vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and GENCOR INDUSTRIES INC (GENC). Click either name above to swap in a different company.
GENCOR INDUSTRIES INC is the larger business by last-quarter revenue ($23.6M vs $21.9M, roughly 1.1× Cue Biopharma, Inc.). GENCOR INDUSTRIES INC runs the higher net margin — 14.6% vs 7.2%, a 7.4% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs -25.0%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs -23.9%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
Gencor Industries Inc is a leading manufacturer of heavy construction and infrastructure equipment, specializing in asphalt production plants, thermal combustion systems, and supporting road-building machinery. It primarily serves North American and global construction markets, supplying products to both public sector infrastructure projects and private commercial construction operators.
CUE vs GENC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $23.6M |
| Net Profit | $1.6M | $3.4M |
| Gross Margin | — | 28.7% |
| Operating Margin | 9.0% | 13.2% |
| Net Margin | 7.2% | 14.6% |
| Revenue YoY | 1292.3% | -25.0% |
| Net Profit YoY | 116.7% | -9.8% |
| EPS (diluted) | $0.05 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $23.6M | ||
| Q3 25 | $2.1M | $18.8M | ||
| Q2 25 | $3.0M | $27.0M | ||
| Q1 25 | $421.0K | $38.2M | ||
| Q4 24 | $1.6M | $31.4M | ||
| Q3 24 | $3.3M | $20.9M | ||
| Q2 24 | $2.7M | $25.6M | ||
| Q1 24 | $1.7M | $40.7M |
| Q4 25 | $1.6M | $3.4M | ||
| Q3 25 | $-7.4M | $1.9M | ||
| Q2 25 | $-8.5M | $3.8M | ||
| Q1 25 | $-12.3M | $6.1M | ||
| Q4 24 | — | $3.8M | ||
| Q3 24 | $-8.7M | $1.5M | ||
| Q2 24 | $-10.2M | $2.6M | ||
| Q1 24 | $-12.3M | $6.2M |
| Q4 25 | — | 28.7% | ||
| Q3 25 | — | 24.2% | ||
| Q2 25 | — | 26.5% | ||
| Q1 25 | — | 29.7% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | — | 25.6% | ||
| Q2 24 | — | 23.9% | ||
| Q1 24 | — | 30.3% |
| Q4 25 | 9.0% | 13.2% | ||
| Q3 25 | -353.4% | -1.2% | ||
| Q2 25 | -292.3% | 11.6% | ||
| Q1 25 | -2921.4% | 17.0% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | -264.2% | 5.9% | ||
| Q2 24 | -390.6% | 7.8% | ||
| Q1 24 | -737.8% | 17.4% |
| Q4 25 | 7.2% | 14.6% | ||
| Q3 25 | -346.6% | 10.2% | ||
| Q2 25 | -287.1% | 14.2% | ||
| Q1 25 | -2911.4% | 16.0% | ||
| Q4 24 | — | 12.1% | ||
| Q3 24 | -259.6% | 6.9% | ||
| Q2 24 | -382.7% | 10.0% | ||
| Q1 24 | -719.1% | 15.3% |
| Q4 25 | $0.05 | $0.23 | ||
| Q3 25 | $-0.07 | $0.13 | ||
| Q2 25 | $-0.09 | $0.26 | ||
| Q1 25 | $-0.17 | $0.42 | ||
| Q4 24 | — | $0.26 | ||
| Q3 24 | $-0.17 | $0.10 | ||
| Q2 24 | $-0.20 | $0.17 | ||
| Q1 24 | $-0.25 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $147.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.4M | $215.2M |
| Total Assets | $42.2M | $228.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $147.7M | ||
| Q3 25 | $11.7M | $136.3M | ||
| Q2 25 | $27.5M | $136.0M | ||
| Q1 25 | $13.1M | $143.7M | ||
| Q4 24 | $22.5M | $130.1M | ||
| Q3 24 | $32.4M | $115.4M | ||
| Q2 24 | $30.0M | $116.6M | ||
| Q1 24 | $41.0M | $117.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | $0 | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | $26.4M | $215.2M | ||
| Q3 25 | $13.2M | $211.8M | ||
| Q2 25 | $18.2M | $209.9M | ||
| Q1 25 | $6.6M | $206.1M | ||
| Q4 24 | $17.5M | $200.0M | ||
| Q3 24 | $25.4M | $196.1M | ||
| Q2 24 | $21.6M | $194.7M | ||
| Q1 24 | $30.0M | $192.1M |
| Q4 25 | $42.2M | $228.9M | ||
| Q3 25 | $31.6M | $222.6M | ||
| Q2 25 | $40.7M | $220.2M | ||
| Q1 25 | $22.3M | $223.9M | ||
| Q4 24 | $32.2M | $218.2M | ||
| Q3 24 | $44.8M | $208.1M | ||
| Q2 24 | $42.3M | $201.8M | ||
| Q1 24 | $54.0M | $206.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | 0.00× | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $11.1M |
| Free Cash FlowOCF − Capex | — | $10.1M |
| FCF MarginFCF / Revenue | — | 43.0% |
| Capex IntensityCapex / Revenue | 0.0% | 4.1% |
| Cash ConversionOCF / Net Profit | -0.68× | 3.23× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-3.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $11.1M | ||
| Q3 25 | $-9.0M | $-275.0K | ||
| Q2 25 | $-3.4M | $-23.9M | ||
| Q1 25 | $-8.2M | $12.4M | ||
| Q4 24 | $-36.3M | $14.8M | ||
| Q3 24 | $-7.5M | $-3.2M | ||
| Q2 24 | $-10.0M | $-1.0M | ||
| Q1 24 | $-9.8M | $11.7M |
| Q4 25 | — | $10.1M | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | $-3.4M | $-24.4M | ||
| Q1 25 | $-8.3M | $12.3M | ||
| Q4 24 | $-36.4M | $14.5M | ||
| Q3 24 | $-7.5M | $-3.3M | ||
| Q2 24 | $-10.0M | $-1.4M | ||
| Q1 24 | $-9.8M | $11.7M |
| Q4 25 | — | 43.0% | ||
| Q3 25 | — | -6.8% | ||
| Q2 25 | -116.5% | -90.4% | ||
| Q1 25 | -1976.7% | 32.2% | ||
| Q4 24 | -2309.3% | 46.1% | ||
| Q3 24 | -225.7% | -15.8% | ||
| Q2 24 | -376.2% | -5.6% | ||
| Q1 24 | -573.0% | 28.7% |
| Q4 25 | 0.0% | 4.1% | ||
| Q3 25 | 0.0% | 5.4% | ||
| Q2 25 | 0.9% | 1.8% | ||
| Q1 25 | 35.6% | 0.4% | ||
| Q4 24 | 4.2% | 1.0% | ||
| Q3 24 | 0.0% | 0.4% | ||
| Q2 24 | 0.4% | 1.5% | ||
| Q1 24 | 3.2% | 0.0% |
| Q4 25 | -0.68× | 3.23× | ||
| Q3 25 | — | -0.14× | ||
| Q2 25 | — | -6.24× | ||
| Q1 25 | — | 2.04× | ||
| Q4 24 | — | 3.88× | ||
| Q3 24 | — | -2.22× | ||
| Q2 24 | — | -0.41× | ||
| Q1 24 | — | 1.87× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
GENC
Segment breakdown not available.
